LARVOL is pleased to present a moderated discussion with top oncologists following IASLC 2021 World Conference on Lung Cancer. In the video below, Dr. Mark Awad, Dr. Ticiana Leal and Dr. Joshua Reuss discuss the practice-changing impact of WCLC presentations in Lung cancer.
On September 16th, 2021, LARVOL hosted an Oncology Panel to discuss the top Lung Cancer clinical trial abstracts presented during the IASLC 2021 World Conference on Lung Cancer, held on September 8-14, 2021. Dr. Mark Awad from Dana-Farber Cancer Institute moderated the discussion between Lung Cancer experts Dr. Ticiana Leal from Emory University School of Medicine and Dr. Joshua Reuss from Georgetown Lombardi Cancer Center.
The discussion covered WCLC Abstracts:
• OA15.03: Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS
• PL02.05: IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab
• PL02.01: Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
Watch this video for the full discussion:
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy
Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network